Sheaff Brock Investment Advisors LLC maintained its stake in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,150 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Sheaff Brock Investment Advisors LLC’s holdings in Intercept Pharmaceuticals were worth $381,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 132 shares during the period. US Bancorp DE acquired a new stake in shares of Intercept Pharmaceuticals in the 1st quarter worth approximately $130,000. IFP Advisors Inc lifted its stake in shares of Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 730 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Intercept Pharmaceuticals in the 1st quarter worth approximately $170,000. Finally, Aperio Group LLC acquired a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter worth approximately $212,000. 82.19% of the stock is owned by institutional investors.
In related news, CEO Mark Pruzanski sold 1,434 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $121.78, for a total transaction of $174,632.52. Following the transaction, the chief executive officer now owns 570,284 shares of the company’s stock, valued at approximately $69,449,185.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Lisa Bright sold 394 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $121.33, for a total transaction of $47,804.02. Following the transaction, the insider now directly owns 23,619 shares in the company, valued at approximately $2,865,693.27. The disclosure for this sale can be found here. Insiders have sold a total of 48,013 shares of company stock worth $6,198,747 in the last three months. 4.50% of the stock is owned by insiders.
WARNING: This article was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://sportsperspectives.com/2017/09/11/sheaff-brock-investment-advisors-llc-maintains-stake-in-intercept-pharmaceuticals-inc-icpt.html.
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) opened at 116.91 on Monday. The stock’s 50 day moving average is $113.00 and its 200-day moving average is $117.24. The firm’s market cap is $2.93 billion. Intercept Pharmaceuticals, Inc. has a 12-month low of $96.63 and a 12-month high of $172.95.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The business had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. During the same quarter last year, the firm earned ($3.14) EPS. Intercept Pharmaceuticals’s quarterly revenue was up 459.6% compared to the same quarter last year. On average, analysts anticipate that Intercept Pharmaceuticals, Inc. will post ($14.05) EPS for the current fiscal year.
A number of brokerages have recently weighed in on ICPT. Credit Suisse Group set a $201.00 price target on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 3rd. BidaskClub raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Laidlaw reissued a “hold” rating and set a $119.00 target price (up from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and set a $275.00 target price on shares of Intercept Pharmaceuticals in a research note on Sunday, July 30th. Finally, Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $200.00 target price on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $205.04.
Intercept Pharmaceuticals Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.